Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety.


Journal

United European gastroenterology journal
ISSN: 2050-6406
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807

Informations de publication

Date de publication:
06 2019
Historique:
received: 20 01 2019
accepted: 13 03 2019
entrez: 19 6 2019
pubmed: 19 6 2019
medline: 19 6 2019
Statut: ppublish

Résumé

The use of an indwelling peritoneal catheter system in hospitalized patients with ascites could facilitate patient management by the prevention of repetitive abdominal paracentesis. Despite these possible benefits, the use of indwelling catheters is not widely established. This retrospective study aimed to evaluate the feasibility, effectiveness and safety of the use of an indwelling catheter for ascites drainage in the clinical routine. This retrospective study included all indwelling peritoneal catheter placements in our department in hospitalized patients with cirrhosis between 2014 and 2017. A total of 324 indwelling catheter placements for ascites in 192 hospitalized patients with cirrhosis were included. The catheter (7F, 8 cm) was placed ultrasound-assisted bed-side on the hospital ward. The technical success rate of the catheter placement was 99.7% (323/324). In 17.5% (64/324) the catheter was placed to optimize ascitic drainage prior to an abdominal intervention (e.g. transjugular intrahepatic portosystemic shunt). The median time of catheter retention was 48 hours (8-168 hours) and the median cumulative amount of drained ascites 8000 ml (550-28,000). The most common adverse event was acute kidney injury (49/324, 15.1%); the risk was particularly higher in patients with a Model for End-Stage Liver Disease (MELD) score ≥ 16 ( The placement of an indwelling catheter for repetitive ascitic drainage in hospitalized patients with cirrhosis can be established in the clinical routine, facilitating patient management. High-MELD patients especially have to be monitored for acute kidney injury.

Sections du résumé

Background
The use of an indwelling peritoneal catheter system in hospitalized patients with ascites could facilitate patient management by the prevention of repetitive abdominal paracentesis. Despite these possible benefits, the use of indwelling catheters is not widely established.
Objective
This retrospective study aimed to evaluate the feasibility, effectiveness and safety of the use of an indwelling catheter for ascites drainage in the clinical routine.
Methods
This retrospective study included all indwelling peritoneal catheter placements in our department in hospitalized patients with cirrhosis between 2014 and 2017.
Results
A total of 324 indwelling catheter placements for ascites in 192 hospitalized patients with cirrhosis were included. The catheter (7F, 8 cm) was placed ultrasound-assisted bed-side on the hospital ward. The technical success rate of the catheter placement was 99.7% (323/324). In 17.5% (64/324) the catheter was placed to optimize ascitic drainage prior to an abdominal intervention (e.g. transjugular intrahepatic portosystemic shunt). The median time of catheter retention was 48 hours (8-168 hours) and the median cumulative amount of drained ascites 8000 ml (550-28,000). The most common adverse event was acute kidney injury (49/324, 15.1%); the risk was particularly higher in patients with a Model for End-Stage Liver Disease (MELD) score ≥ 16 (
Conclusion
The placement of an indwelling catheter for repetitive ascitic drainage in hospitalized patients with cirrhosis can be established in the clinical routine, facilitating patient management. High-MELD patients especially have to be monitored for acute kidney injury.

Identifiants

pubmed: 31210945
doi: 10.1177/2050640619842442
pii: 10.1177_2050640619842442
pmc: PMC6545707
doi:

Types de publication

Journal Article

Langues

eng

Pagination

673-681

Références

Semin Intervent Radiol. 2006 Jun;23(2):165-76
pubmed: 21326760
Gastroenterology Res. 2015 Aug;8(3-4):228-233
pubmed: 27785301
AJR Am J Roentgenol. 2011 Mar;196(3):675-85
pubmed: 21343513
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
J Hepatol. 2006 Jan;44(1):217-31
pubmed: 16298014
Dan Med Bull. 2011 Jan;58(1):A4212
pubmed: 21205563
Am J Gastroenterol. 2019 Jan;114(1):40-47
pubmed: 29973706
J Hepatol. 2015 Apr;62(4):968-74
pubmed: 25638527
Am J Gastroenterol. 1996 Sep;91(9):1731-3
pubmed: 8792689
Med Klin (Munich). 2001 Jun 15;96(6):321-4
pubmed: 11450583
Clin Gastroenterol Hepatol. 2009 Aug;7(8):906-9
pubmed: 19447197
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
Dig Dis Sci. 2016 Oct;61(10):3084-3092
pubmed: 27048451
J Hepatol. 2013 Sep;59(3):474-81
pubmed: 23669284
Can J Gastroenterol Hepatol. 2016;2016:4680543
pubmed: 27446840
Gastroenterology. 1988 Jun;94(6):1493-502
pubmed: 3360270
Hepatology. 2003 May;37(5):1147-53
pubmed: 12717396
Aliment Pharmacol Ther. 2005 Mar 1;21(5):525-9
pubmed: 15740535
Gut. 2011 May;60(5):702-9
pubmed: 21325171
Eur J Gastroenterol Hepatol. 2017 May;29(5):539-546
pubmed: 28350743
Gut. 1999 Oct;45 Suppl 4:IV1-IV11
pubmed: 10485854

Auteurs

Katharina Stratmann (K)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Daniel Fitting (D)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Stefan Zeuzem (S)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Jörg Bojunga (J)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Jonel Trebicka (J)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Mireen Friedrich-Rust (M)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Georg Dultz (G)

Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Frankfurt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH